The Role of Niacin in Raising HDL-C to Reduce Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Optimally Treated LDL-C AIM-HIGH: Rationale and Study Design

摘要

BackgroundTo test the hypothesis that patients with atherosclerotic cardiovascular (CV) disease optimally treated on a statin but with residual atherogenic dyslipidemia (low HDL-C and high triglycerides) will benefit from addition of niacin with fewer CV events compared with placebo.Statin monotherapy trials have found 25–40% CV risk reduction relative to placebo, leaving significant residual risk. Patients with atherogenic dyslipidemia have substantially increased CV risk.